Back

Select your region

Corporate

Europe:

Flag Albania Albania Flag Bosnia and Herzegovina Bosnia and Herzegovina Flag Bulgaria Bulgaria Flag Croatia Croatia Flag Cyprus Cyprus Flag Montenegro Montenegro Flag Czech Republic Czech Republic Flag Denmark Denmark Flag Estonia Estonia Flag Spain Spain Flag Kosovo Kosovo Flag Lithuania Lithuania Flag Latvia Latvia Flag Luxembourg Luxembourg Flag Macedonia Macedonia Flag Germany Germany Flag Poland Poland Flag Portugal Portugal Flag Romania Romania Flag Serbia Serbia Flag Slovakia Slovakia Flag Slovenia Slovenia Flag Switzerland Switzerland Flag Sweden Sweden Flag Turkey Turkey Flag Hungary Hungary Flag United Kingdom United Kingdom Flag Italy Italy

Asia:

Flag UAE UAE Flag Hong Kong Hong Kong Flag Kuwait Kuwait Flag Lebanon Lebanon

Africa:

Flag South Africa South Africa

Arrange a consultation about stem cells

Learn more

Get in touch with us today!

Would you like to find out more about our services? Fill out the form below and we will contact you as soon as possible to provide you with all the necessary information and answer your questions.

    We would like to point out that the personal data provided in the form will be processed by FamiCord Suisse, based in Switzerland (BusinessPark Zug Sumpfstrasse 26, 6302 Zug), for the purpose of contacting you by telephone in connection with the provision of service information.

    Image

    List of
    transplantations

    List of uses for stem cells approved by the FamiCord Group’s laboratories:

    Image
    List of uses for stem cells approved by the FamiCord Group’s laboratories:
    Nr. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
    1601 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 63
    1602 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 50
    1603 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 60
    1604 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 30
    1605 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 68
    1606 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 77
    1607 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 60
    1608 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 47
    1609 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 62
    1610 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 65
    1611 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 64
    1612 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 61
    1613 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 64
    1614 Apheresis Allogeneic Acute Myelogenous Leukemia- Core-Binding Factor Hematology 2024 Standard Therapy Poland 68
    1615 Apheresis Allogeneic Acute Myelogenous Leukemia, Post Myelofibrosis Hematology 2024 Standard Therapy Poland 63
    1616 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 36
    1617 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 46
    1618 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 48
    1619 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 52
    1620 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 58
    1621 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 61
    1622 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Poland 67
    1623 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 71
    1624 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 72
    1625 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 63
    1626 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 32
    1627 Apheresis Autologous Acute Myeloid Leukemia – Relapse Hematology 2024 Standard Therapy Germany 68
    1628 Apheresis Allogeneic Acute Myeloid Leukemia Relapse Hematology 2024 Standard Therapy Germany 33
    1629 Apheresis Allogeneic Amegakaryocytic/Congenital Thrombocytopenia Hematology 2024 Standard Therapy Poland 63
    1630 Apheresis Allogeneic Anaplastic Large Cell Lymphoma Hematology 2024 Standard Therapy Poland 52
    1631 Apheresis Allogeneic Angioimmunoblastic T-Cell Lymphoma Hematology 2024 Standard Therapy Poland 47
    1632 Apheresis Allogeneic B-Cell Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 19
    1633 Apheresis Allogeneic B-Cell Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 62
    1634 Apheresis Allogeneic B-Cell Progenitor Acute Lymphoblastic Leukemia High Risk Hematology 2024 Standard Therapy Poland 4
    1635 Apheresis Allogeneic Calr Positive Myelofibrosis Hematology 2024 Standard Therapy Poland 61
    1636 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2024 Standard Therapy Poland 60
    1637 Apheresis Allogeneic Chronic Myelogenous Leukaemia Hematology 2024 Standard Therapy Poland 62
    1638 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 10
    1639 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 35
    1640 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 42
    1641 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 49
    1642 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 72
    1643 Apheresis Allogeneic Chronic Neutrophilic Leukemia Hematology 2024 Standard Therapy Poland 71
    1644 Apheresis Allogeneic Fanconi Aplastic Anemia Hematology 2024 Standard Therapy Poland 20
    1645 Apheresis Allogeneic Follicular Lymphoma Hematology 2024 Standard Therapy Poland 48
    1646 Apheresis Allogeneic High Risk Acute Myeloid Leukaemia Hematology 2024 Standard Therapy Poland 15
    1647 Apheresis Allogeneic High Risk Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 69
    1648 Apheresis Allogeneic High-Risk Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 71
    1649 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 27
    1650 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 27
    1651 Apheresis Allogeneic Hodgkin Disease Hematology 2024 Standard Therapy Poland 28
    1652 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 23
    1653 Apheresis Allogeneic Hypoplastic Myelodysplastic Syndrome/Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 71
    1654 Apheresis Allogeneic Infant Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 41
    1655 Apheresis Allogeneic Kutanes T-Zell-Lymphom, Mycosis Fungoides Hematology 2024 Standard Therapy Poland 72
    1656 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 51
    1657 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 64
    1658 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 66
    1659 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 52
    1660 Apheresis Autologous Morbus Hodgkin Hematology 2024 Standard Therapy Germany 63
    1661 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Poland 43
    1662 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 52
    1663 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 54
    1664 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 60
    1665 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
    1666 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1667 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1668 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1669 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1670 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 63
    1671 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 64
    1672 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 65
    1673 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 65
    1674 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
    1675 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
    1676 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 67
    1677 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 68
    1678 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 69
    1679 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 70
    1680 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 71
    1681 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 72
    1682 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
    1683 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1684 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 58
    1685 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
    1686 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
    1687 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1688 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 70
    1689 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 74
    1690 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 58
    1691 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 63
    1692 Apheresis Allogeneic Myelodysplastic Hematology 2024 Standard Therapy Poland 68
    1693 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 20
    1694 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 22
    1695 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 54
    1696 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 58
    1697 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 60
    1698 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 62
    1699 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 65
    1700 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67